KR102864779B1 - 세라마이드 및 이의 관상동맥질환 진단 용도 - Google Patents

세라마이드 및 이의 관상동맥질환 진단 용도

Info

Publication number
KR102864779B1
KR102864779B1 KR1020247004744A KR20247004744A KR102864779B1 KR 102864779 B1 KR102864779 B1 KR 102864779B1 KR 1020247004744 A KR1020247004744 A KR 1020247004744A KR 20247004744 A KR20247004744 A KR 20247004744A KR 102864779 B1 KR102864779 B1 KR 102864779B1
Authority
KR
South Korea
Prior art keywords
formula
ceramide
carbon atoms
alkyl chain
cer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247004744A
Other languages
English (en)
Korean (ko)
Other versions
KR20240023696A (ko
Inventor
레이조 라크소넨
Original Assignee
조라 바이오사이언시즈 오와이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조라 바이오사이언시즈 오와이 filed Critical 조라 바이오사이언시즈 오와이
Priority to KR1020257030977A priority Critical patent/KR20250139419A/ko
Publication of KR20240023696A publication Critical patent/KR20240023696A/ko
Application granted granted Critical
Publication of KR102864779B1 publication Critical patent/KR102864779B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247004744A 2014-06-16 2015-06-16 세라마이드 및 이의 관상동맥질환 진단 용도 Active KR102864779B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257030977A KR20250139419A (ko) 2014-06-16 2015-06-16 세라마이드 및 이의 관상동맥질환 진단 용도

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462012543P 2014-06-16 2014-06-16
US62/012,543 2014-06-16
US14/677,595 US9347960B2 (en) 2014-06-16 2015-04-02 Ceramides and their use in diagnosing CVD
US14/677,595 2015-04-02
KR1020177000864A KR102636885B1 (ko) 2014-06-16 2015-06-16 세라마이드 및 이의 관상동맥질환 진단 용도
PCT/EP2015/063492 WO2015193325A2 (en) 2014-06-16 2015-06-16 Ceramides and their use in diagnosing cvd

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177000864A Division KR102636885B1 (ko) 2014-06-16 2015-06-16 세라마이드 및 이의 관상동맥질환 진단 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257030977A Division KR20250139419A (ko) 2014-06-16 2015-06-16 세라마이드 및 이의 관상동맥질환 진단 용도

Publications (2)

Publication Number Publication Date
KR20240023696A KR20240023696A (ko) 2024-02-22
KR102864779B1 true KR102864779B1 (ko) 2025-09-25

Family

ID=54835950

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247004744A Active KR102864779B1 (ko) 2014-06-16 2015-06-16 세라마이드 및 이의 관상동맥질환 진단 용도
KR1020257030977A Pending KR20250139419A (ko) 2014-06-16 2015-06-16 세라마이드 및 이의 관상동맥질환 진단 용도
KR1020177000864A Active KR102636885B1 (ko) 2014-06-16 2015-06-16 세라마이드 및 이의 관상동맥질환 진단 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257030977A Pending KR20250139419A (ko) 2014-06-16 2015-06-16 세라마이드 및 이의 관상동맥질환 진단 용도
KR1020177000864A Active KR102636885B1 (ko) 2014-06-16 2015-06-16 세라마이드 및 이의 관상동맥질환 진단 용도

Country Status (10)

Country Link
US (5) US9347960B2 (cg-RX-API-DMAC7.html)
EP (2) EP3155440B1 (cg-RX-API-DMAC7.html)
JP (1) JP6774879B2 (cg-RX-API-DMAC7.html)
KR (3) KR102864779B1 (cg-RX-API-DMAC7.html)
CN (1) CN106461685B (cg-RX-API-DMAC7.html)
CA (1) CA2951578A1 (cg-RX-API-DMAC7.html)
MX (1) MX380642B (cg-RX-API-DMAC7.html)
SA (1) SA516380503B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201609621RA (cg-RX-API-DMAC7.html)
WO (1) WO2015193325A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9347960B2 (en) * 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD
WO2016100549A2 (en) * 2014-12-16 2016-06-23 Washington University Ceramides for evaluating risk of cardiovascular disease
EP3714273A1 (en) * 2017-11-20 2020-09-30 Zora Biosciences OY Methods for prediction and early detection of diabetes
CN114062581A (zh) * 2017-12-14 2022-02-18 江苏豪思生物科技有限公司 一种用于评估冠状动脉疾病的试剂盒
WO2020112149A1 (en) * 2018-12-01 2020-06-04 Binhai Industrial Technology Research Institute Of Zhejiang University Methods and compositions for the assessment of acute myocardial infarction (ami)
WO2020115288A1 (en) * 2018-12-06 2020-06-11 Zora Biosciences Oy Biomarkers for cardiovascular events
CN112730638B (zh) * 2020-11-25 2022-07-29 首都医科大学附属北京朝阳医院 糖尿病合并心梗代谢标志物、检测试剂及试剂盒
CN112986454A (zh) * 2021-05-18 2021-06-18 天津云检医疗器械有限公司 急性心肌梗死的血清标志物、试剂盒和用途
CN113495160B (zh) * 2021-09-07 2021-11-19 宝枫生物科技（北京）有限公司 用于诊断高原环境下的缺血缺氧性脑病补充神经酸起效的分子标志物及其应用
WO2023108294A1 (en) * 2021-12-17 2023-06-22 National Research Council Of Canada Diagnostic lipid biomarkers for covid-19 and methods for use thereof
CN116500179B (zh) * 2023-04-21 2023-12-26 南京品生医疗科技有限公司 一种血浆中神经酰胺相关因子的原始得分计算及转换方法和系统
CN119198939B (zh) * 2024-08-30 2025-06-03 北京大学第三医院（北京大学第三临床医学院） 神经酰胺的检测试剂盒、应用检测试剂盒检测神经酰胺的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068374A2 (en) 2011-11-08 2013-05-16 Zora Biosciences Oy Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
WO2013068373A2 (en) 2011-11-08 2013-05-16 Zora Biosciences Oy Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
JP2013531238A (ja) 2010-06-20 2013-08-01 ゾラ バイオサイエンシーズ オサケ ユキチュア 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9285378B2 (en) 2010-01-29 2016-03-15 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
ES2455124T5 (es) 2010-05-05 2018-05-08 Zora Biosciences Oy Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca
US9541565B2 (en) 2011-04-08 2017-01-10 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
AU2012288742B2 (en) 2011-07-28 2016-12-08 Ruprecht-Karls-Universitaet Heidelberg Means and methods for diagnosing and monitoring heart failure in a subject
ES2686542T3 (es) 2012-10-18 2018-10-18 Metanomics Gmbh Medios y procedimientos para determinar una cantidad normalizada de aclaramiento de un biomarcador de enfermedad metabólica en una muestra
EP2965092A1 (en) 2013-03-08 2016-01-13 Zora Biosciences OY Non-high density lipoprotein derived cvd markers
US9347960B2 (en) * 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531238A (ja) 2010-06-20 2013-08-01 ゾラ バイオサイエンシーズ オサケ ユキチュア 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー
WO2013068374A2 (en) 2011-11-08 2013-05-16 Zora Biosciences Oy Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
WO2013068373A2 (en) 2011-11-08 2013-05-16 Zora Biosciences Oy Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSU& TURK et al., JACS MASS SPECTR., 2002, Vol. 13, pp 558-570. 1부.
TARASOV et al., ‘Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency’, J. CLIN. ENDOCRIN. METABOL., 2013, Vol. 99, pp E45-E52. 1부.*

Also Published As

Publication number Publication date
JP6774879B2 (ja) 2020-10-28
KR20240023696A (ko) 2024-02-22
SA516380503B1 (ar) 2023-03-23
WO2015193325A3 (en) 2016-02-25
US9347960B2 (en) 2016-05-24
BR112016028534A2 (pt) 2017-08-22
EP3155440A2 (en) 2017-04-19
US20220163547A1 (en) 2022-05-26
US20150362513A1 (en) 2015-12-17
WO2015193325A2 (en) 2015-12-23
US11474116B2 (en) 2022-10-18
CN106461685B (zh) 2021-05-25
SG11201609621RA (en) 2017-01-27
US11940453B2 (en) 2024-03-26
US20190113531A1 (en) 2019-04-18
US20240183866A1 (en) 2024-06-06
KR102636885B1 (ko) 2024-02-19
EP3155440B1 (en) 2022-04-20
EP4089416A1 (en) 2022-11-16
US20160266152A1 (en) 2016-09-15
MX2016016742A (es) 2017-04-27
CN106461685A (zh) 2017-02-22
KR20170018905A (ko) 2017-02-20
KR20250139419A (ko) 2025-09-23
CA2951578A1 (en) 2015-12-23
JP2017519989A (ja) 2017-07-20
US10197582B2 (en) 2019-02-05
MX380642B (es) 2025-03-12

Similar Documents

Publication Publication Date Title
US11940453B2 (en) Ceramides and their use in diagnosing CVD
Nikolic et al. Metabolomics in hypertension
CN108445241B (zh) 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
Deidda et al. Metabolomics, a promising approach to translational research in cardiology
Afshinnia et al. Lipidomics and biomarker discovery in kidney disease
WO2011063470A1 (en) Lipid biomarkers for stable and unstable heart disease
AU2011209431A1 (en) Means and methods for diagnosing heart failure in a subject
Zeng et al. Identification of serum biomarker in acute aortic dissection by global and targeted metabolomics
CN113396334A (zh) 用于心血管事件的生物标志物
CN114062581A (zh) 一种用于评估冠状动脉疾病的试剂盒
US20190086386A1 (en) USE OF CERAMIDES AND LPLs IN DIAGNOSING CVD
CN118409095A (zh) 用于诊断冠状动脉狭窄程度的代谢标志物及其应用
JP2016532115A (ja) 被験体において心不全を診断するための手段及び方法
WO2011089146A1 (en) Method for assaying diseases characterised by dyslipidemia
HK40083140A (en) Ceramides and their use in diagnosing cardiovascular diseases
HK1230721A1 (en) Ceramides and their use in diagnosing cvd
HK1230721B (en) Ceramides and their use in diagnosing cvd
Ricciardi Fibrillazione atriale nell’anziano: dalla valutazione clinica alle indagini dimetabolomica. Un approccio multidimensionale per lo studio di un’aritmia complessa. Atrial fibrillation in the elderly: From multidimensional assessment to a metabolomic insight. A complex approach for a complex arrhythmia.
BR112016028534B1 (pt) Composição compreendendo ceramidas, kits e métodos in vitro para determinar o risco do desenvolvimento de doenças ou complicações cardiovasculares, avaliar e escolher tratamentos
Grau et al. Bringing Human Serum Lipidomics
Lindahl Gaps in Our Biomarker Armamentarium: What Novel Biomarkers Might Be Synergistic in Patients with Acute Disease
Oh Medium-Chain Acylcarnitines Are Associated With Cardioembolic Stroke and Stroke Recurrence: A Metabolomics Study

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)